Robyn Karnauskas
Stock Analyst at Truist Securities
(2.40)
# 2,606
Out of 5,044 analysts
181
Total ratings
42.58%
Success rate
0.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRML Tourmaline Bio | Downgrades: Hold | $63 → $48 | $47.98 | +0.04% | 3 | Sep 10, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $5.63 | +77.62% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $292.09 | +2.02% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $42.82 | +51.80% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $87.03 | +26.39% | 11 | Jan 8, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,033 → $1,029 | $820.10 | +25.47% | 5 | Oct 31, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $117.88 | -29.59% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $227.54 | -7.71% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.38 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $149.13 | +127.99% | 17 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 | $1.50 | +1,633.33% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.74 | +302.30% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $654.48 | +73.42% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.55 | +545.16% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $4.40 | +104.55% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $18.41 | +24.93% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $21.98 | +118.38% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $19.88 | +151.51% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $422.39 | +20.27% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $24.50 | +46.94% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $67.48 | -62.95% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.18 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $53.49 | +161.73% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $4.20 | +714,185.71% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.49 | +369.80% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $70.00 | -21.43% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $18.49 | +1,630.67% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $19.25 | -22.06% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $1.30 | +6,438.46% | 1 | Oct 8, 2020 |
Tourmaline Bio
Sep 10, 2025
Downgrades: Hold
Price Target: $63 → $48
Current: $47.98
Upside: +0.04%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $5.63
Upside: +77.62%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $292.09
Upside: +2.02%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $42.82
Upside: +51.80%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $87.03
Upside: +26.39%
Eli Lilly and Company
Oct 31, 2024
Maintains: Buy
Price Target: $1,033 → $1,029
Current: $820.10
Upside: +25.47%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $117.88
Upside: -29.59%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $227.54
Upside: -7.71%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.38
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $149.13
Upside: +127.99%
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.50
Upside: +1,633.33%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.74
Upside: +302.30%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $654.48
Upside: +73.42%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.55
Upside: +545.16%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $4.40
Upside: +104.55%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $18.41
Upside: +24.93%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $21.98
Upside: +118.38%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $19.88
Upside: +151.51%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $422.39
Upside: +20.27%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $24.50
Upside: +46.94%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $67.48
Upside: -62.95%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.18
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $53.49
Upside: +161.73%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $4.20
Upside: +714,185.71%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.49
Upside: +369.80%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $70.00
Upside: -21.43%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $18.49
Upside: +1,630.67%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $19.25
Upside: -22.06%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $1.30
Upside: +6,438.46%